Frontage Laboratories Overview
- Founded
-
2001
- Status
-
Public
- Employees
-
1,698
- Stock Symbol
-
01521
- Investments
-
13
- Share Price
-
$0.26
- (As of Friday Closing)
Frontage Laboratories General Information
Description
Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.
Contact Information
- 700 Pennsylvania Drive
- Exton, PA 19341
- United States
Frontage Laboratories Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.26 | $0.27 | $0.20 - $0.43 | $554M | 2.04B | 1.35M | $0.01 |
Frontage Laboratories Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 762,260 | 762,260 | 893,563 | 947,380 |
| Revenue | 250,360 | 250,360 | 184,441 | 125,811 |
| EBITDA | 69,413 | 69,413 | 49,670 | 29,906 |
| Net Income | 25,735 | 25,735 | 18,428 | 17,150 |
| Total Assets | 550,594 | 550,594 | 475,842 | 382,714 |
| Total Debt | 118,186 | 118,186 | 57,850 | 40,622 |
Frontage Laboratories Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Frontage Laboratories Comparisons
Industry
Financing
Details
00000
000000
Frontage Laboratories Competitors (10)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| North American Science Associates | Private Equity-Backed | Northwood, OH | 0000 | 000.00 | 000000000 | 000.00 |
| 0000000 00000 0000 | Formerly PE-Backed | Wilmington, MA | 00000 | 00000 | 00000000000 | 00000 |
| 000000 0000 000000 | Private Equity-Backed | Hyderabad, India | 0000 | 0000 | 00000000000 | 0000 |
| 0000 000000 | Formerly PE-Backed | Shanghai, China | 00000 | 00.000 | 000000000 | 00.000 |
| 000000 000000 | Corporation | Morrisville, NC | 00000 | 00000 | 000000000000 | 00000 |
Frontage Laboratories Executive Team (8)
Frontage Laboratories Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000 000 000 | Self | Board Member | 000 0000 |
| 0000 00 00.0 | Frontage Laboratories | Chief Executive Officer & Chairman | 000 0000 |
| 00000 00 | Self | Board Member | 000 0000 |
| 00000 00 | Frontage Laboratories | Board Member | 000 0000 |
Frontage Laboratories Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Frontage Laboratories Investments & Acquisitions (13)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 00000 0 | 08-Sep-2021 | 0000000000 | Other Healthcare Services | 0000 00 0 | |
| 00000000 0000 | 26-Jun-2021 | 0000000000 | 0000 | Drug Discovery | 0000 00 0 |
| 00000 00000 0 | 19-Apr-2021 | 0000000000 | Biotechnology | ||
| 000000000 | 11-Jan-2021 | 0000000000 | Biotechnology | 0000 00 0 | |
| Acme Bioscience | 02-Jul-2020 | Merger/Acquisition | 0000 | Practice Management (Healthcare) | 0000 00 0 |
Frontage Laboratories Subsidiaries (3)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Quintara Discovery | Drug Discovery | Hayward, CA | 2012 |
| 0000 0000000000 | Practice Management (Healthcare) | Palo Alto, CA | 0000 |
| 00000 00000 000000 | Other Healthcare Services | Wuhan, China |
Frontage Laboratories ESG
Risk Overview
Risk Rating
Updated April, 30, 2022
23.55 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,912
Rank
Percentile
Pharmaceuticals
Industry
00 of 965
Rank
Percentile
Biotechnology
Subindustry
00 of 443
Rank
Percentile
